Non-small cell lung cancer with iris metastasis controlled with osimertinib and monthly intravitreal bevacizumab
Purpose: Iris metastases from lung cancer occur rarely. Current treatment options such as surgical iridectomy or radiotherapy are invasive and can potentially lead to negative side effects. Other less invasive alternatives include chemotherapy and intracameral bevacizumab. Observations: An 81 year-o...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-03-01
|
| Series: | American Journal of Ophthalmology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2451993622000159 |
| _version_ | 1819283872025673728 |
|---|---|
| author | Margaret Wong James H. Frank Carol L. Shields |
| author_facet | Margaret Wong James H. Frank Carol L. Shields |
| author_sort | Margaret Wong |
| collection | DOAJ |
| description | Purpose: Iris metastases from lung cancer occur rarely. Current treatment options such as surgical iridectomy or radiotherapy are invasive and can potentially lead to negative side effects. Other less invasive alternatives include chemotherapy and intracameral bevacizumab. Observations: An 81 year-old female with metastatic non-small cell lung adenocarcinoma to the iris in the right eye was treated with daily oral osimertinib 80mg, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), for her systemic lung cancer. In addition, 8 monthly intravitreal bevacizumab (1.25mg/0.05 cc) injections were given. The iris tumor demonstrated complete regression by the third cycle of osimertinib. Following 21 months of osimertinib and 8 bevacizumab injections, the tumor remained regressed. Subsequent iris biopsy confirmed complete tumor regression. Conclusions and Importance: In this case, osimertinib and monthly intravitreal bevacizumab controlled iris metastasis due to non-small cell lung cancer. Osimertinib can be beneficial for patients with EGFR-positive lung cancer for both ocular and systemic control. |
| first_indexed | 2024-12-24T01:38:22Z |
| format | Article |
| id | doaj.art-2311f5a9a80c4015a5ebd77163380642 |
| institution | Directory Open Access Journal |
| issn | 2451-9936 |
| language | English |
| last_indexed | 2024-12-24T01:38:22Z |
| publishDate | 2022-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Journal of Ophthalmology Case Reports |
| spelling | doaj.art-2311f5a9a80c4015a5ebd771633806422022-12-21T17:22:07ZengElsevierAmerican Journal of Ophthalmology Case Reports2451-99362022-03-0125101269Non-small cell lung cancer with iris metastasis controlled with osimertinib and monthly intravitreal bevacizumabMargaret Wong0James H. Frank1Carol L. Shields2Private Practice, Eye Consultants of Atlanta, 3225 Cumberland Boulevard, Suite 800, Atlanta, GA, 30339, USA; Corresponding author. Eye Consultants of Atlanta, 3225 Cumberland Boulevard, Suite 800, Atlanta, GA, 30339, USA.Private Practice, Eye Consultants of Atlanta, 3225 Cumberland Boulevard, Suite 800, Atlanta, GA, 30339, USAOcular Oncology Service, Wills Eye Hospital, 840 Walnut Street, Suite 1440, Philadelphia, PA, 19107, USAPurpose: Iris metastases from lung cancer occur rarely. Current treatment options such as surgical iridectomy or radiotherapy are invasive and can potentially lead to negative side effects. Other less invasive alternatives include chemotherapy and intracameral bevacizumab. Observations: An 81 year-old female with metastatic non-small cell lung adenocarcinoma to the iris in the right eye was treated with daily oral osimertinib 80mg, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), for her systemic lung cancer. In addition, 8 monthly intravitreal bevacizumab (1.25mg/0.05 cc) injections were given. The iris tumor demonstrated complete regression by the third cycle of osimertinib. Following 21 months of osimertinib and 8 bevacizumab injections, the tumor remained regressed. Subsequent iris biopsy confirmed complete tumor regression. Conclusions and Importance: In this case, osimertinib and monthly intravitreal bevacizumab controlled iris metastasis due to non-small cell lung cancer. Osimertinib can be beneficial for patients with EGFR-positive lung cancer for both ocular and systemic control.http://www.sciencedirect.com/science/article/pii/S2451993622000159Non-small cell lung cancerOsimertinibBevacizumabIrisMetastasis |
| spellingShingle | Margaret Wong James H. Frank Carol L. Shields Non-small cell lung cancer with iris metastasis controlled with osimertinib and monthly intravitreal bevacizumab American Journal of Ophthalmology Case Reports Non-small cell lung cancer Osimertinib Bevacizumab Iris Metastasis |
| title | Non-small cell lung cancer with iris metastasis controlled with osimertinib and monthly intravitreal bevacizumab |
| title_full | Non-small cell lung cancer with iris metastasis controlled with osimertinib and monthly intravitreal bevacizumab |
| title_fullStr | Non-small cell lung cancer with iris metastasis controlled with osimertinib and monthly intravitreal bevacizumab |
| title_full_unstemmed | Non-small cell lung cancer with iris metastasis controlled with osimertinib and monthly intravitreal bevacizumab |
| title_short | Non-small cell lung cancer with iris metastasis controlled with osimertinib and monthly intravitreal bevacizumab |
| title_sort | non small cell lung cancer with iris metastasis controlled with osimertinib and monthly intravitreal bevacizumab |
| topic | Non-small cell lung cancer Osimertinib Bevacizumab Iris Metastasis |
| url | http://www.sciencedirect.com/science/article/pii/S2451993622000159 |
| work_keys_str_mv | AT margaretwong nonsmallcelllungcancerwithirismetastasiscontrolledwithosimertinibandmonthlyintravitrealbevacizumab AT jameshfrank nonsmallcelllungcancerwithirismetastasiscontrolledwithosimertinibandmonthlyintravitrealbevacizumab AT carollshields nonsmallcelllungcancerwithirismetastasiscontrolledwithosimertinibandmonthlyintravitrealbevacizumab |